Advicenne Prepares For Launch As Rare Kidney Disease Drug Is Filed In The EU
Executive Summary
Having had a bid for accelerated assessment rejected by the EMA last year, the French biotech is getting a standard review for ADV7103 in dRTA patients and hopes to launch late 2020.